Study With Quadrivalent Recombinant Influenza Vaccine (RIV4) in Participants 9 Through 49 Years of Age.
Clinical trial NCT05513053 · COMPLETED
Trial details
- NCT number
- NCT05513053
- Sponsor
- Sanofi Pasteur, a Sanofi Company
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2022-10-27
- Primary completion
- 2023-10-27
- Enrollment
- 1308
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.